Avid Bioservices Inc (CDMO)

[hutschi]

Maybe Novartis is trying to speed up:

Oncology Venture Enters into Option Agreement with Novartis Pharma to License Small Molecule Compound - MarketLine
22-Jul-2017 00:20:05
Oncology Venture AB, a company engaged in the R&D of anti-cancer drugs, has entered into an agreement with Novartis Pharma AG, a pharmaceutical company, providing Oncology Venture with an option right to execute an exclusive license to develop and commercialize an undisclosed small molecule, kinase inhibitor in clinical development. The molecule has been explored in multiple therapeutic indications including a variety of solid tumors. Under the option agreement, Oncology Venture will evaluate whether it can suitably develop and validate a companion diagnostic for the drug using its proprietary DRP biomarker platform. This agreement will enable Oncology Venture and Novartis Pharma to evaluate the potential of a small molecule compound for development in cancer.

This agreement will enable Oncology Venture and Novartis Pharma to evaluate the potential of a small molecule compound for development in cancer.

Deal In Brief

Deal Type Partnership
Sub-Category Licensing Agreement
Deal Status Announced: 2017-07-19


Deal Participants

Partner 1 (Company) Novartis Pharma AG Partner 2 (Company) Oncology Venture Sweden AB


Deal Rationale

Copyright (c) 2001-2016 Marketline.